The Asia Pacific Recombinant Proteins Market would witness market growth of 11.4% CAGR during the forecast period (2022-2028).
Prokaryotic recombinant proteins are proteins that have been cloned in a prokaryotic system and encoded by a gene (recombinant DNA) (E.coli). Prokaryotic recombinant proteins are a good choice for chronic therapy for a number of autoimmune illnesses due to their high specificity and low immunogenicity.
The recombinant protein market is dominated by monoclonal antibodies. The World Health Organization (WHO) predicts that by 2030, chronic diseases like diabetes, cancer, cardiovascular disease, and others will overtake all other causes of death to rank seventh globally. Because prokaryotic recombinant proteins have more advantages and less adverse effects when treating autoimmune and chronic diseases, this will propel the market for these proteins to increase.
The rising geriatric population within regional nations is one of the main factors driving an increase in the utilisation of protein therapies. Chinese citizens accounted up 18% of the world's population in 2019, the National Library of Medicine reports, with 164.5 million of them aged 65 or older and 26 million being 80 or more. The expansion of the recombinant protein market in this region is projected to be aided by the creation of new products and partnership initiatives by biotechnology firms.
The China market dominated the Asia Pacific Recombinant Proteins Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $195.1 million by 2028. The Japan market is estimated to grow a CAGR of 10.7% during (2022 - 2028). Additionally, The India market would experience a CAGR of 12.1% during (2022 - 2028).
Based on Product, the market is segmented into Growth Factors & Chemokines, Recombinant Metabolic Enzymes, Adhesion Molecules & Receptors, Structural Proteins, Membrane Proteins, Kinase Proteins & Regulatory Proteins, Immune Response Proteins, and Others. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical Companies, Biotechnology Companies, Academic Research Institutes, Contract Research Organizations, and Others. Based on Application, the market is segmented into Drug Discovery & Development, Academic Research Studies, Biopharmaceutical Production, Diagnostics, Biotechnology Research, and Others. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Recombinant Proteins Market is Projected to reach USD 2.6 Billion by 2028, at a CAGR of 10.8%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bio-Techne Corporation, Thermo Fisher Scientific, Inc., Merck Group, Bio-Rad Laboratories, Inc., Abcam plc, Genscript Biotech Corporation, Miltenyi Biotec B.V. & Co. KG, Proteintech Group, Inc., BPS Bioscience, Inc., and RayBiotech Life, Inc.
By Product
By End User
By Application
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
